ALL 001, NCT03962465: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL |
|
|
| Active, not recruiting | 1 | 36 | US | Inotuzumab ozogamicin, Besponsa, Prednisone Pill, Deltasone, Daunorubicin, Cerubidine, daunomycin, rubidomycin, Vincristine, Oncovin, Vincasar, Leurocristine, Cytarabine, Ara-C, Cytosar-U, Methotrexate, Otrexup, Rasuvo, Rheumatrex, Trexall, MTX, Amethopterin, Pegaspargase, Oncospar | University of Virginia, Pfizer, Vanderbilt University, University of Wisconsin, Madison, Virginia Commonwealth University | B-cell Acute Lymphoblastic Leukemia | 07/23 | 07/26 | | |